Skip to main content

Table 2 Crude and adjusted hazard ratios for the association between the use of antipsychotics and breast cancer-specific mortality

From: Post-diagnostic antipsychotic use and cancer mortality: a population based cohort study

  Users Non-Users Unadjusted HR (95% CI) Adjusted a
HR (95% CI)
N Person years Cancer deaths N Person years Cancer deaths
All antipsychotics 848 3190 165 22,847 123,106 2896 2.42 (2.07–2.83) 2.25 (1.90–2.67)
 1–182 DDDs v non-user 638 2271 148 22,847 123,106 2896 2.95 (2.50–3.48) 2.56 (2.15–3.04)
 182+ DDDs v non-user 210 919 17 22,847 123,106 2896 0.95 (0.59–1.53) 0.93 (0.56–1.53)
1st generation antipsychotics 558 2288 124 23,137 124,008 2937 2.62 (2.19–3.13) 2.41 (2.00–2.91)
 1–182 DDDs v non-user 462 1787 115 23,137 124,008 2937 3.04 (2.52–3.67) 2.69 (2.22–3.25)
 182+ DDDs v non-user 96 501 9 23,137 124,008 2937 0.94 (0.49–1.80) 0.92 (0.47–1.81)
 Fupentixol 108 507 14 23,587 125,789 3047 1.36 (0.81–2.30) 1.45 (0.85–2.45)
 Promazine 162 447 45 23,533 125,849 3016 4.82 (3.59–6.47) 3.34 (2.48–4.50)
 Trifluoperazine 71 432 10 23,624 125,865 3051 1.11 (0.60–2.07) 1.12 (0.60–2.10)
 Haloperidol 142 400 50 23,553 125,896 3011 5.71 (4.32–7.56) 4.42 (3.32–5.89)
2nd generation antipsychotics 377 1264 45 23,318 125,032 3016 1.60 (1.19–2.15) 1.26 (0.91–1.73)
 1–182 DDDs v non-user 251 810 37 23,318 125,032 3016 1.96 (1.41–2.71) 1.48 (1.05–2.08)
 182+ DDDs v non-user 126 454 8 23,318 125,032 3016 0.87 (0.43–1.73) 0.70 (0.34–1.44)
 Olanzapine 138 546 18 23,557 125,750 3043 1.57 (0.99–2.50) 1.25 (0.76–2.03)
 Risperidone 130 463 17 23,565 125,833 3044 1.67 (1.04–2.69) 1.27 (0.78–2.07)
 Quetiapine 133 360 12 23,562 125,937 3049 1.55 (0.88–2.73) 1.20 (0.67–2.13)
1st generation antipsychotics only 471 1926 120 22,847 123,106 2896 2.94 (2.44, 3.53) 2.75 (2.28, 3.32)
2nd generation antipsychotics only 290 902 41 22,847 123,106 2896 1.95 (1.43, 2.65) 1.67 (1.21, 2.32)
1st and 2nd generation use 87 362 4 22,847 123,106 2896 0.64 (0.24, 1.69) 0.57 (0.21, 1.54)
Prolactin elevating antipsychotics b 668 2644 139 23,027 123,652 2922 2.50 (2.11–2.96) 2.27 (1.90–2.72)
 1–182 DDDs v non-user 568 2127 130 23,027 123,652 2922 2.84 (2.38–3.39) 2.47 (2.06–2.96)
 182+ DDDs v non-user 100 518 9 23,027 123,652 2922 0.91 (0.47–1.76) 0.92 (0.47–1.81)
Prolactin-sparing antipsychotics c 267 869 30 23,428 125,427 3031 1.58 (1.10–2.27) 1.27 (0.87–1.87)
 1–182 DDDs v non-user 144 420 22 23,428 125,427 3031 2.24 (1.47–3.40) 1.75 (1.14–2.69)
 182+ DDDs v non-user 123 448 8 23,428 125,427 3031 0.88 (0.44–1.75) 0.70 (0.34–1.44)
  1. a Model contains age, year of diagnosis, treatment within 6 months (separate variables for radiootherapy, chemotherapty, surgery, tamoxifen and aromatase inhibitor use), comorbidities (prior to diagnosis including serious mental illness, chronic pulmonary disease, diabetes, renal disease, cerebrovascular disease, peripheral vascular disease, myocardial infarction, peptic ulcer disease and liver disease), hormonal medication use (oral contraceptive and hormone replacement therapy, prior to diagnosis), other medication use (statin and aspirin as time varying covariates) and deprivation (in fifths)
  2. b Prolactin elevating antipsychotics included chlorpromazine,flupentixol,fluphenazine, haloperidol, pericyazine, perphenazine, pimozide, pipotiazine, promazine, trifluoperazine, zuclopenthixol, amisulpride, risperidone and sulpiride
  3. c Prolactin non-elevating antipsychotics included aripiprazole, olanzapine, quetiapine and sertindole